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Background: Combining maintenance medications with different mechanisms of action may
improve outcomes in COPD. In this study we evaluated the efficacy and safety of flutica-
sone/salmeterol (FSC) (250/50 mcg twice daily) when added to tiotropium (18 mcg once daily)
(TIO) in subjects with symptomatic moderate to severe COPD.
Methods: This was a 24-week, randomized, double-blind, parallel group, multi-center study.
Subjects 40 years or older with cigarette smoking history 10 pack-years and with the diag-
nosis of COPD and post-bronchodilator FEV1 40 to  80% of predicted normal and FEV1/
FVC of 0.70 were enrolled. Following a 4-week treatment with open-label TIO 18 mcg once
daily, subjects were randomized in a double-blind fashion to either the addition of FSC 250/
50 DISKUS twice daily or matching placebo. The primary efficacy endpoint was AM pre-dose
FEV1 and secondary endpoints included other measures of lung function, rescue albuterol
use, health status and exacerbations.
Results: The addition of FSC to TIO significantly improved lung function indices including AM pre-
dose FEV1, 2 h post-dose FEV1, AM pre-dose FVC, 2 h post-dose FVC and AM pre-dose IC compared
with TIO alone. Furthermore, this combination was superior to TIO alone in reducing rescue al-
buterol use. However, there were no significant differences between the treatment groups in
health status or COPD exacerbations. The incidence of adverse events was similar in both groups.
Conclusions: The addition of FSC to subjects with COPD treated with TIO significantly improves
lung function without increasing the risk of adverse events. NCT00784550.
ª 2011 Elsevier Ltd. All rights reserved.483 8225; fax: þ1 919 483 4300.
k.com (G.D. Crater).
1 Elsevier Ltd. All rights reserved.
92 N.A. Hanania et al.Introduction infection that required treatment with antibiotics, systemicChronic Obstructive Pulmonary Disease (COPD) is one of the
leading causes of morbidity and mortality worldwide.1,2 The
most distinguishing feature of COPD is dyspnea which can be
related to airflow obstruction and hyperinflation as docu-
mented by spirometric evaluation. Current treatment
guidelines for COPD emphasize the need for treating symp-
tomatic patients with this disease. Treatments include
pharmacological and non-pharmacological interventions
which are used in a stepwise fashion according to severity.
Inhaled pharmacotherapy, consisting of a long-acting beta2-
agonist, a long-acting muscarinic antagonist, an inhaled
corticosteroid (not indicated for the treatment of COPD as
monotherapy), or some combination of the preceding, is the
foundation formanaging stable COPD. Asmonotherapy, each
of these three classes of drugs improves lung function, and
health status, and reduces the risk of exacerbations; all to
a similarly modest extent.3 However, important questions
remain as to the clinical benefit, cost, safety, and appro-
priate target populationwhen these classes of drugs are used
in combination in patients with symptomatic COPD.
The rationale for prescribing a long-acting beta2 agonist
along with inhaled corticosteroids in COPD patients is well
established, and these two classes of drugs are available as
combined formulations of fluticasone/salmeterol, budeso-
nide/formoterol, and mometasone/formoterol (currently
only approved for asthma).4e7 The combined fluticasone/
salmeterol formulation and the once daily inhaled anti-
cholinergic, tiotropium, are currently the two most widely
prescribed COPD medications and they appear to confer
similar clinical benefits without clear superiority of one
over the other.8 Fluticasone/salmeterol and tiotropium are
frequently used together as so-called “triple therapy”, but
this clinical practice is based on inadequate evidence. Two
small, short-term trials yielded conflicting results as to
whether the combination of fluticasone/salmeterol and
tiotropium improved lung function over that obtained with
either fluticasone/salmeterol or tiotropium alone.9,10 In
a larger one-year trial, fluticasone/salmeterol added to
tiotropium did not reduce COPD exacerbations to a greater
extent than tiotropium alone, the primary outcome, but did
improve selected secondary outcomes, including lung
function and respiratory health status.11 In this study we
evaluated the efficacy and safety of fluticasone/salmeterol
(FSC) (250/50 mcg twice daily) when added to tiotropium
(TIO) (18 mcg once daily), compared to TIO alone in
symptomatic subjects with moderate to severe COPD.
Methods
Study design
This was a 24-week, randomized, double-blind, parallel
group study conducted at 33 centers in the US (study code
ADC111114, NCT 00784550). After initial evaluation, eligible
subjects completed a 4-week run-in period in which open-
label TIO only was administered. Following run-in, subjects
who had a modified Medical Research Council dyspnea scale
score of 2 were eligible for randomization.12 Subjects who
experienced a COPD exacerbation or respiratory tractcorticosteroids, or hospitalization during the run-in period
were excluded. Subjects were randomized in a 1:1 double-
blind fashion to open-label TIO 18 mcg once daily via Hand-
iHaler plus FSC 250/50 mcg via DISKUS (FSC; Advair, Sere-
tide, GlaxoSmithKline, Research Triangle Park, NC, USA)
twice daily or open-label TIO 18 mcg once daily plus Placebo
DISKUS twice daily. Treatment groups were stratified by
albuterol reversibility to ensure the proportion of subjects
with albuterol reversibility was similar across groups. The
use of concurrent inhaled long-acting bronchodilators
(beta2-agonist and anticholinergic), ipratropium/albuterol
combination products, oral beta2-agonists, inhaled and oral
corticosteroids, and theophylline preparations were not
allowed during the treatment period. Albuterol was supplied
as rescue medication during run-in and throughout the rest
of the study. A follow-up phone call was performed
approximately 2 weeks following the end of study treatment
period or early withdrawal visit. The study was approved by
the institutional review board or ethics committee of each
site, and all participants provided written informed consent
prior to conduct of study procedures.
Study population
Inclusion criteria to be enrolled in this study were: age 40
years and older, diagnosis of COPD according to ATS-ERS
criteria, cigarette smoking history 10 pack-years, post-
albuterol FEV1 40 to  80% of predicted normal and
a post-albuterol FEV1/FVC of 0.70 according to NHANES III
reference values.13,14 Principal exclusion criteria were:
clinical diagnosis of respiratory disorder other than COPD,
long-term oxygen, BMI 40 kg/m2, clinically significant and
uncontrolled medical disorder, lung resection surgery
within the past year, and inability to give informed consent.
Efficacy assessments
The primary efficacy measure was AM pre-dose FEV1 at
endpoint (the last scheduledmeasure of pre-dose FEV1 during
the 24-week treatment period). Secondary efficacy measures
included 2 h post-dose FEV1, AM pre-dose FVC, 2 h post-dose
FVC, AM pre-dose IC, and domain scores on the Chronic
Respiratory Disease Questionnaire-Self-Administered Stan-
dardized (CRQ-SAS), all at endpoint.15 Other efficacy
measures included rescue albuterol use and health care
utilization for COPD exacerbations. Exploratory endpoints
included scores on the Quick Inventory of Depressive
Symptomatology-Self Report (QIDS-SR) scale and scoreson the
Hospital Anxiety and Depression Scale (HADS).16,17 The CRQ-
SAS, QIDS-SR, and HADS were self-administered by the study
subjects. Use of the CRQ-SAS, authored byDrs. GordonGuyatt
and Holger Schunemann, was granted under license from
McMaster University, Hamilton, Canada.
Pulmonary function testing was conducted at screening
(for albuterol reversibility testing) and at randomization
and weeks 4, 8, 16, 24. Centralized spirometry services
were provided by nSpire Health, Inc. of Longmont, CO, US.
The CRQ-SAS, QIDS-SR, and HADS were all assessed at
randomization and at weeks 8 and 24 and the early with-
drawal visit. Subjects completed diary cards daily to record
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open-label TIO. Treatment compliance with the study
HandiHaler and DISKUS was determined by dividing total
number of inhalations recorded in the subject diary card by
the total number of inhalations prescribed  100.
Safety assessments
Safety was assessed by standard adverse event monitoring
procedures, including the incidence and type of pneumonia.
Statistical analysis
Statistical analyses were performed using SAS version 9.1
software in a UNIX reporting environment. Using a two-
sample two-sided t-test with a standard deviation estimate
of 250 mL for pre-dose FEV1 change from baseline, 133
subjects per treatment group were needed to detect
a significant difference of 100 mL between treatment
groups at the 0.05 significance level with 90% power. The
analysis population was the Intent-to-treat population
which included all subjects randomized to study drug. The
target enrollment of approximately 350 randomized
subjects allowed for early discontinuations from the study.
The primary efficacymeasure was change from baseline in
pre-dose FEV1 at endpoint where endpoint was defined as the
last scheduled measure of pre-dose FEV1 during the 24-week633 patients screene
63 (10%) excluded during run-in 
3 missing 
14 adverse event 
11 protocol deviation 
8 lost to follow-up 
14 investigator discretion 
13 withdrew consent 
342 patients ra
173 assigned to FSC + Tio 
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0 lack of efficacy 
10 protocol deviation 
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12 adverse event 
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Figure 1 Constreatment period. The primary efficacy measure and
secondary efficacymeasures of pre-dose FVC and IC, 2-h post-
dose FEV1 and FVC, and CRQ-SAS scores were compared
between treatment groups using analysis of covariance
(ANCOVA) with terms for treatment group, investigator,
reversibility stratum and baseline value. The analysis of COPD
exacerbations compared the rate of exacerbations per
subject per the 24-week treatment period between treat-
ment groups using a Poisson regressionmodel, including terms
for treatment group, pooled investigator, reversibility
stratum and baseline severity (baseline FEV1 percent pre-
dicted), with log (time of treatment) as an offset variable.
Rescue albuterol use and QIDS-SR and HADS scores were
compared between treatment groupswith an ANCOVAmodel.
A hierarchical testing procedure to control type I error
for multiplicity was used for the treatment comparisons of
efficacy endpoints. The Hochberg method was also used to
control the overall type I error rate across the secondary
efficacy measures. Exploratory analyses were not adjusted
for multiplicity.
Results
Study subjects
A total of 633 subjects were screened, 342 were
randomized, and 264 (77%) completed the study (Fig. 1).d for eligibility
228 (36%) excluded at Screening 
220 entry criteria not met 
1 protocol deviation 
1 lost to follow-up 
1 investigator discretion 
5 withdrew consent 
ndomized 
169 assigned to Tio 
42 (25%) withdrew 
10 adverse event 
1 lack of efficacy 
10 protocol deviation 
5 lost to follow-up 
3 investigator discretion 
13 withdrew consent 
127 (75%) completed the study 
ort Diagram.
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study compared with 127 (75%) subjects in the TIO group.
A total of 78 subjects (36 in the FSC þ TIO group and 42 in
the TIO group) prematurely withdrew from the study. The
most common reason for premature withdrawal was
adverse event. Demographic and baseline characteristics
are summarized in Table 1. Overall, demographics were
similar between the two groups, but slightly more males
were enrolled in the FSC þ TIO group (50%) compared with
the TIO group (43%).
Lung function
During the run-in, treatment with open-label TIO signifi-
cantly increased mean pre-dose FEV1 from screening levels
(increases of 100  20 mL; p < 0.001) for within group
change from screening. Mean change from baseline at
endpoint (last scheduled measure of pre-dose FEV1 during
the 24-week treatment period) was 101  21.8 mL in the
FSC þ TIO group and 16  20.4 mL in the TIO group (least
squares (LS) mean difference of 115 mL, p < 0.001).
Significant improvements for this endpoint were seen with
the FSC þ TIO group compared with the TIO group at Weeks
4, 8, 16, and 24, (Fig. 2a.).The mean change from baseline
at endpoint in post-dose FEV1 was 233  23.1 mL in the
FSC þ TIO group and 77  20.6 mL in the TIO group (LS
mean difference of 154 mL, p < 0.001). The differences in
improvement of this endpoint were also significant for
subjects treated with FSC þ TIO compared with TIO atTable 1 Demographic and Baseline Characteristics.
FSC þ TIO
(n Z 173)
TIO
(n Z 169)
Age, mean (years) 61.3 61.0
Gender, % male 50% 43%
Race, %White/%African American 95/4 96/4
Duration COPD, mean (years) 6.9 6.4
Current Smoker, % 59% 57%
Pack-Years, mean 55.4 54.7
Reversible, n (%)a 64 (37) 61 (36)
BMI, mean (kg/m**2) 27.0 27.6
Post-Bronchodilator FEV1 L,
(% predicted)
1.67, (56) 1.70, (57.4)
GOLD Stage II (n, %) 109 (63) 122 (72)
GOLD Stage III (n, %) 64 (37) 47 (28)
Exacerbations in past 12 mos requiring hospitalization, n (%)
0 165 (95) 162 (96)
1 8 (5) 6 (4)
2 0 1 (<1)
Exacerbations in past 12 mos requiring oral corticosteroids/
antibiotic, n (%)
0 117 (68) 125 (74)
1 45 (26) 35 (21)
2 7 (4) 6 (4)
3 4 (2) 3 (2)
Mean mMRC Dyspnea Score 2.4 2.5
a defined as a post-albuterol increase in FEV1 of 200 mL and
12% from the pre-albuterol baseline.Weeks 4, 8, 16, and 24 (Fig. 2b). During run-in, treatment
with open-label TIO statistically significantly increased
mean AM pre-dose FVC from screening levels (increases of
130  30 mL and 140  30 mL in subjects subsequently
randomized to FSC þ TIO and TIO, respectively, p < 0.001
for within group change from screening). Mean change from
baseline at endpoint in AM pre-dose FVC was 95  32.7 mL
in the FSC þ TIO group and 28  30.6 mL in the TIO group
(LS mean difference of 122 mL, p Z 0.006). The differ-
ences in improvement of this endpoint were also significant
in the FSC þ TIO group compared with the TIO group at
Weeks 4, 8, 16, and 24 (Fig. 3a). Mean change from base-
line at endpoint in post-dose FVC was 265  35.9 mL in the
FSC þ TIO group and 87  31.2 mL in the TIO group (LS
mean difference of 175 mL, p < 0.001). These improve-
ments were also significant with the FSC þ TIO group
compared with the TIO group at Weeks 4, 8, 16, and 24
(Fig. 3b). Mean change from baseline at endpoint in AM
pre-dose IC was 107  28.4 mL in the FSC þ TIO group and
8  28.1 mL in the TIO group (LS mean difference of
141 mL, p < 0.001). These improvements were also
significant with the FSC þ TIO group compared with the TIO
group at Weeks 4, 8, 16, and 24 (Fig. 3c). Lung function
endpoints for subjects with 50% and >50% predicted pre-
bronchodilator FEV1 at baseline are summarized in Table 2.
In summary, the FSC þ TIO group exhibited a statistically
significant improvement from baseline at endpoint
compared with the TIO group for all lung function measures
examined. In subjects with moderate COPD (FEV1>50%
predicted), the FSC þ TIO group exhibited a statistically
significant improvement from baseline at endpoint
compared with the TIO group for 2 h post-dose FEV1.
However, for all other lung function endpoints, the
differences between the FSC þ TIO and TIO groups were
not statistically significant.Rescue albuterol use
Mean baseline values for albuterol use were 2.3 puffs/day
in both the FSC þ TIO and TIO groups. At endpoint,
albuterol use was reduced to 1.8 puffs/day in the
FSC þ TIO group and increased to 2.4 puffs/day in the TIO
group with an LS mean difference (SE) of 0.6 (0.24),
p Z 0.010. Albuterol use was statistically significantly
reduced in the FSC þ TIO group compared with the TIO
group when evaluated over 1e24 weeks and over 4 week
periods throughout the study except at Weeks 17e20
when the difference between groups was not statistically
significant (Fig. 4).Health status
A summary of CRQ-SAS domain scores (mastery, fatigue,
emotional function, and dyspnea) at baseline and endpoint
is provided in Table 3. There were no statistically significant
changes from baseline to endpoint on any domain score
between the two groups.
Figure 2 a&b Change in FEV1.
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There were 25 (14%) and 26 (15%) subjects in the FSC þ TIO
and TIO groups who experienced 26 and 30 exacerbations,
respectively. The mean exacerbation rate was not statisti-
cally significantly different between the groups (0.14 and
0.17 in the FSC þ TIO and TIO groups, respectively,
p Z 0.531). The rate of exacerbations by HCU (i.e., use ofsystemic corticosteroids and/or antibiotics, unscheduled or
urgent care physician/clinic office visits, hospitalizations
and/or emergency room visits) could not be calculated due
to the low number of events in each group. Most of the
exacerbations (92% in the FSC þ TIO group and 73% in the
TIO group) did not result in an urgent care, ER visit, or
hospital stay. The majority of exacerbations resulted in one
office visit (20 [77%] and 18 [60%]) in the FSC þ TIO and TIO
Figure 3 a,b &c Changes in FVC and IC.
Table 2 Differences in Lung Function Endpoints for Subjects with 50% and >50% predicted pre-bronchodilator FEV1 at
Baseline.
50% >50%
FSC þ TIO n Z 66 TIO n Z 61 FSC þ TIO n Z 104 TIO n Z 107
AM Pre-Dose FEV1 at Endpoint (mL)
LS Mean Difference, (SE) 202 (46.1) 50 (36.8)
p value <0.001 0.178
2 H Post-Dose FEV1 at Endpoint (mL)
LS Mean Difference, (SE) 258 (49.3) 82 (36.6)
p value <0.001 0.026
AM Pre-Dose FVC at Endpoint (mL)
LS Mean Difference, (SE) 203 (74.5) 40 (50.8)
p value 0.007 0.431
2 H Post-Dose FVC at Endpoint (mL)
LS Mean Difference, (SE) 268 (85.6) 84 (47.8)
p value 0.002 0.081
AM Pre-Dose IC at Endpoint (mL)
LS Mean Difference, (SE) 218 (64.5) 53 (49.4)
p value 0.001 0.286
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Figure 4 Rescue Albuterol Use.
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exacerbations in the FSC þ TIO and TIO groups, respec-
tively, were treated with a course of oral corticosteroids
while 23 (88%) and 17 (57%) exacerbations in the FSC þ TIO
and TIO groups, respectively, were treated with antibiotics.Exploratory endpoints
At endpoint, themeanQID-SR scores were 6.2 and 6.8 for the
FSC þ TIO and TIO groups, respectively. The differenceTable 3 Other Secondary Endpoints.
FSC þ TIO (n Z 173)
CRQ-SAS
Mastery
BL, mean 4.98
Endpoint, mean 5.23
Fatigue
BL, mean 3.91
Endpoint, mean 4.10
Emotional Function
BL, mean 4.59
Endpoint, mean 4.81
Dyspnea
BL, mean 4.72
Endpoint, mean 4.88
COPD Exacerbations
Subjects w/an exacerbation, n (%) 25 (14)
Number of COPD exacerbation 26
Mean exacerbation rate 0.14
BL Z Baseline.between groups at endpoint was not statistically signifi-
cantly different (LS mean difference of 0.0 and SE of 0.37,
pZ 0.947). A total of 70 and 71 subjects in the FSCþ TIO and
TIO groups, respectively, met the criteria of having at least
mild depression (score of6 at baseline). When the analysis
was performed with subjects whomet the criteria of at least
mild depression at baseline, there was also no statistically
significant difference between groups (Table 4).
There were no statistically significant differences
between groups on the HADS at endpoint (LS mean differ-
ence of 0.1 and SE of 0.28, p Z 0.789). A total of 35 andTIO (n Z 169) LS Mean difference p-value
5.05 0.2 0.069
5.09
3.82 0.09 0.470
3.97
4.56 0.08 0.394
4.71
4.66 0.02 0.879
4.85
26 (15)
30
0.17 0.531
Table 4 Scores on the QIDS-SR and Depression and
Anxiety Scores on the HADS.
FSC þ TIO
n Z 173
TIO
n Z 169
QIDS-SR
n 163 155
BL Mean Score (SE) 5.9 (0.31) 6.6 (0.38)
Endpoint
n 152 157
Mean Score (SE) 6.2 (0.35) 6.8 (0.37)
Change from BL
n 144 145
Mean Score (SE) 0.3 (0.28) 0.1 (0.28)
LS Mean Difference, (SE) 0.0 (0.37)
p value 0.947
HADS
Depression Scale
n 168 163
BL Mean Score (SE) 4.6 (0.29) 4.8 (0.30)
Endpoint
n 157 163
Mean Score (SE) 4.6 (0.31) 4.8 (0.31)
Change from BL
n 154 158
Mean Score (SE) 0.1(0.22) 0.1(0.19)
LS Mean Difference, (SE) 0.1(0.28)
p value 0.789
Anxiety Scale
n 169 164
BL Mean Score (SE) 4.9 (0.31) 5.5 (0.33)
Endpoint
n 155 161
Mean Score (SE) 5.1 (0.34) 5.1 (0.35)
Change from BL
n 153 158
Mean Score (SE) 0.0 (0.26) 0.4 (0.23)
LS Mean Difference, (SE) 0.3 (0.32)
p value 0.438
BL Z Baseline.
Table 5 Most Common (>2%) Adverse Events During
Treatment.
FSC þ TIO
n Z 173
TIO
n Z 169
Any event n, % 97 (56) 85 (50)
Chronic obstructive
pulmonary disease
24 (14) 24 (14)
Headache 11 (6) 9 (5)
Back pain 5 (3) 9 (5)
Nasopharyngitis 5 (3) 6 (4)
Oropharyngeal pain 6 (3) 4 (2)
Bronchitis 6 (3) 3 (2)
Oral candidiasis 5 (3) 1 (<1)
Dyspnea 0 5 (3)
98 N.A. Hanania et al.40 subjects in the FSC þ TIO and TIO groups, respectively,
met the criteria of having at least mild depression on the
HADS (score of 8 at baseline). When the analysis was
performed with subjects who met the criteria of at least
mild depression at baseline, there was also no statistically
significant difference between groups. A total of 42 and 49
subjects in the FSC þ TIO and TIO groups, respectively, met
the criteria of having at least mild anxiety on the HADS
(score of 8 at baseline). When the analysis was performed
with subjects who met the criteria of at least mild anxiety
at baseline, there was also no statistically significant
difference between groups (Table 4).Safety
Adverse events were reported for a slightly higher
percentage of subjects in the FSC þ TIO (56%) groupcompared with the TIO (50%) group (Table 5). A total of 7
(4%) and 13 (8%) subjects in the FSC þ TIO and TIO groups,
respectively experienced an SAE. The most frequent SAE
was COPD occurring in 5 (3%) subjects in the TIO group. All
other SAEs occurred in <1% of subjects in each group. Two
subjects in the FSC þ TIO group experienced pneumonia
during treatment.Discussion
Management of COPD aims to control symptoms, improve
pulmonary function and reduce exacerbations. Mainte-
nance medications which include long-acting bronchodila-
tors as stand alone or in combination with inhaled
corticosteroids are recommended by evidence-based
guidelines for all patients with symptomatic COPD.18
Recent COPD guidelines have recommended that
combining bronchodilators with different mechanisms and
durations of action may increase the degree of bronchodi-
lation for equivalent or lesser side effects.18 In this study,
we evaluated the efficacy and safety of administering
“triple therapy” with tiotropium, and FSC combination in
subjects with moderate to severe COPD compared to the
use of tiotropium alone. The results of our 24-week study
demonstrate a clear superiority for this approach of
combination therapy when added to tiotropium in
improving all indices of lung function and reducing rescue
medication use without any increase incidence of adverse
events compared to when tiotropium was used alone. These
effects are more pronounced in patients with severe
disease (pre-bronchodilator FEV1 50% predicted).
Tiotropium and FSC are the two most prescribed medi-
cations for the treatment of COPD, and are frequently co-
prescribed in clinical practice. Tiotropium has been shown
to be effective in improving trough FEV1, dyspnea, health
status, and exacerbations compared to placebo.19e21
Randomized trials have demonstrated that treatment with
FSC at strengths of 250/50 mcg and 500/50 mcg BID results
in greater improvement in lung function and dyspnea
compared with the individual components in patients with
COPD.22e24 In the United States (US), only the 250/50
strength of FSC is indicated for the twice daily maintenance
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associated with chronic bronchitis or emphysema and for
the reduction of exacerbations in patients with chronic
obstructive pulmonary disease (COPD) who have a history of
exacerbations.
While intuitively, the combination of FSC with tio-
tropium confers additional benefit in COPD compared to
single bronchodilator (i.e., tiotropium) alone, there are
only a few studies to support this. Furthermore there are
also limited data on the use of such combination in
patients with moderate disease. A 3-month pilot study of
treatment of FSC 500/50 plus placebo, tiotropium plus
placebo, or FSC 500/50 plus tiotropium showed that all
groups had significant improvements in trough FEV1 at the
end of the study compared to baseline. However, the
greatest difference occurred in the FSC 500/50 plus tio-
tropium group.9 Another study11 compared the effect of
FSC 250/25 plus tiotropium, tiotropium plus salmeterol,
and tiotropium plus placebo over one year. The study was
not adequately powered to show a statistically significant
difference among groups on the primary endpoint of
exacerbations. However, the FSC plus tiotropium group
improved lung function, hospitalizations for exacerbations
and St. George’s Respiratory Questionnaire (SGRQ) scores
compared to tiotropium plus placebo. Of note, the tio-
tropium plus salmeterol group did not improve these
endpoints compared to tiotropium plus placebo which
suggests that dual bronchodilator therapy was no better
than a single bronchodilator in this study. However, other
studies have indeed shown beneficial effects when two
long-acting bronchodilators are used in combination
compared to monotherapy.25e27 A recent study evaluated
the anti-inflammatory effects of FSC, fluticasone
propionate þ tiotropium or tiotropium alone and demon-
strated that anti-inflammatory effects of fluticasone
propionate in FSC probably contribute to the clinical
benefits seen with this combination.28 Another study10
examined the effect of FSC 500/50 plus tiotropium
compared with either treatment alone. This study showed
that the triple therapy was superior to either agent alone
in AUC0e4hr sGAW and sRAW at 14 days and other lung
function measurements as well as improvement in symp-
tomatic endpoints such as the Transition Dyspnea Index
(TDI) and the use of rescue medication. In another recent
study29 which enrolled patients with severe disease and
past history of COPD exacerbation, the use of another
combination (budesonide/formoterol combination)
conferred significant improvement in lung function, health
status and reduced severe exacerbations when added to
tiotropium when compared to tiotropium alone. Of note,
the triple combination studies mentioned above all
showed statistically significant differences with triple
combination therapy on a variety of lung function and
symptomatic endpoints in COPD. In addition, the patient
populations in these studies ranged from moderate (FEV1
75% predicted normal) to severe (FEV1 <50% predicted
normal) indicating that a wide range of COPD severities do
benefit from triple combination therapy compared to dual
or single bronchodilator therapy alone. However, many of
these studies included a small number of subjects,
focused on a subgroup of severe COPD and/or examined
the higher dose of FSC, 500/50.While treatment guidelines recommend the addition
of ICS as a pharmacotherapy for COPD to patients with
severe disease, the use of “triple therapy” is often used
in clinical practice in the U.S in the general COPD
population. We therefore elected to evaluate the
effects of such combination in a real life scenario and
thus included a wider range of COPD patients using the
FSC dose formulation currently approved in the U.S. The
trial was designed to include a larger proportion of
subjects with GOLD Stage 2 disease than have been
enrolled in most previous trials evaluating inhaled
pharmacotherapy in COPD.10 We also did not restrict this
combination therapy to subjects with previous history of
exacerbations as has been done in previous studies. We
demonstrated a significant statistical and clinically
meaningful improvement in lung function measures in
the study population although this improvement was
more pronounced in subjects with more severe disease.
Furthermore, a significant effect on the reduction in the
use of rescue medication supports the positive effects
on lung function observed.
In addition to evaluating the effects of this combination
on lung function, we evaluated the effects on health status
utilizing the CRQ-SAS questionnaire. No statistically signif-
icant differences were found between the FSC þ TIO and
TIO groups on this endpoint. This may be explained by the
fact that subjects in both groups had mild to no impairment
on the domains of the CRQ-SAS at baseline. Therefore,
a treatment effect could not be observed. Further, we did
not demonstrate any superiority of the “triple combina-
tion” in this study to tiotropium alone on exacerbations of
COPD and health care utilization. However, the incidences
of these in both groups were relatively small and the study
was neither powered nor long enough to capture such
events. In addition, we did not enrich the study population
with subjects at risk of exacerbations as we attempted to
evaluate this in subjects with a broad range of COPD
severity.
Because the course of COPD is often complicated by
anxiety and depression, we included the exploratory
endpoints of depression and anxiety in this study. We were
unable to demonstrate any effects of either intervention on
these outcomes in this study. This may be explained by the
fact that the incidence of anxiety and depression at base-
line was modest and the duration of treatment may have
been too short to demonstrate differences. This needs
further exploration in longer term studies that include
patients with more severe disease where the rates of
depression and anxiety are higher.
Our safety surveillance during the study revealed
a reassuring safety profile of the “triple combination” with
no increased incidence of adverse events or serious adverse
events compared to TIO alone therapy.
Our study has several limitations. A longer study
duration may have helped to fully examine the effect of
triple therapy on the incidence of exacerbations. In
addition, quality of life and other endpoints affecting
quality of life (depression and anxiety) were not
improved with a triple therapy regimen, but these
subjects had little to mild impairment on the CRQ-SAS,
QIDS, and HADS upon study entry which precluded
observing a treatment effect.
100 N.A. Hanania et al.In summary, the results of this study support the use of
“triple therapy” in COPD patients to augment the benefits
of tiotropium alone in symptomatic patients with COPD.
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